Acumen stockholders elect two Class III directors, ratify Ernst & Young as auditor for FY2024

Acumen Pharmaceuticals, Inc.

Daniel O'Connell received 40,490,834 votes for, 48,338 withheld; Nathan Fountain 34,164,444 for, 6,371,549 withheld.
Ratification of Ernst & Young as auditor: 52,367,645 for, 7,093 against, 6,271 abstained.
Approximately 87% of outstanding shares (52,381,009 of 60,079,778) were present at the annual meeting.
Directors elected to serve until the 2027 annual meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.